Infinity Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.infi.com
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
- Conditions
- Advanced CancerBladder CancerUrothelial CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03980041
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
🇺🇸Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
- Conditions
- Breast CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT03961698
- Locations
- 🇺🇸
Samsum Clinic, Santa Barbara, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University Cancer & Blood Center, Athens, Georgia, United States
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
- Conditions
- Advanced Solid Tumors (Part A/B/C/D)Triple Negative Breast Cancer (Part F)Adrenocortical Carcinoma (Part G)Non-small Cell Lung Cancer (Part E)Mesothelioma (Part G)High-circulating Myeloid-derived Suppressor Cells (Part H)Melanoma (Part E)Squamous Cell Cancer of the Head and Neck (Part E)
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT02637531
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UCSD, San Diego, California, United States
🇺🇸UCLA, Santa Monica, California, United States
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01609179
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01427946
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2012-11-15
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01371617
- Locations
- 🇺🇸
Arizona Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University School of Medicine, Division of Hematology, Palo Alto, California, United States
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: IPI 504 plus Docetaxel
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT01362400
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States
🇺🇸Texas Oncology-Arlington South, Arlington, Texas, United States
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01310816
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Dose Escalation of IPI-493 in Hematologic Malignancies
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01193491
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Weill Cornell Cancer Center, New York, New York, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01130142
- Locations
- 🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸South Texas Oncology and Hematology, San Antonio, Texas, United States